Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001683168-25-004194
Filing Date
2025-06-03
Accepted
2025-06-03 16:45:09
Documents
17
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 10-K coeptis_10ka1-123124.htm   iXBRL 10-K/A 59330
2 CERTIFICATION coeptis_ex3103.htm EX-31.3 4649
3 CERTIFICATION coeptis_ex3104.htm EX-31.4 4718
4 COEPTIS THERAPEUTICS HOLDINGS, INC. CLAWBACK POLICY coeptis_ex9700.htm EX-97 32177
  Complete submission text file 0001683168-25-004194.txt   358377

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE coep-20241231.xsd EX-101.SCH 3874
6 XBRL DEFINITION FILE coep-20241231_def.xml EX-101.DEF 27187
7 XBRL LABEL FILE coep-20241231_lab.xml EX-101.LAB 37638
8 XBRL PRESENTATION FILE coep-20241231_pre.xml EX-101.PRE 25808
20 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_10ka1-123124_htm.xml XML 8497
Mailing Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Holdings, Inc. (Filer) CIK: 0001759186 (see all company filings)

EIN.: 981465952 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39669 | Film No.: 251020372
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)